Breaking News
December 17, 2018 - How the Mediterranean Diet Can Help Women’s Hearts
December 17, 2018 - Sustained connections associated with symptoms of autism
December 17, 2018 - Concussion rates among young football players were higher than previously reported
December 17, 2018 - Cresco Labs granted approval to operate marijuana dispensary in Ohio
December 17, 2018 - Study provides insight into health risks facing new mothers
December 17, 2018 - AMSBIO expands Wnt signaling pathway product range to aid research
December 16, 2018 - Surgical treatment unnecessary for many prostate cancer patients
December 16, 2018 - Excess weight responsible for cancers globally finds report
December 16, 2018 - Regular sex associated with greater enjoyment of life in seniors
December 16, 2018 - Social stigma contributes to poor mental health in the autistic community
December 16, 2018 - Multidisciplinary team successfully performs complex surgery on patient suffering from enlarged skull
December 16, 2018 - Experts analyze data that can guide antidepressant discontinuation
December 16, 2018 - Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis
December 16, 2018 - Siblings of children with autism or ADHD are at elevated risk for both disorders
December 16, 2018 - New project aims to understand why and how metabolic disorders develop in patients
December 16, 2018 - Diets containing GM maize have no harmful effects on health or metabolism of rats
December 16, 2018 - Are doctors and teachers confusing immaturity and attention deficit?
December 16, 2018 - Hearing loss linked with increased risk for premature death
December 16, 2018 - Chromatrap buffer reagents for lysing cells offer many benefits
December 16, 2018 - Young Breast Cancer Patients Face Higher Risk for Osteoporosis
December 16, 2018 - 3-D printing offers helping hand to people with arthritis
December 16, 2018 - Community Health Choice helps manage complex and chronic care conditions
December 16, 2018 - Regular trips out could dramatically reduce depression in older age
December 16, 2018 - CWRU to use VivaLNK’s Vital Scout device for stress study in student athletes
December 16, 2018 - ‘Easy Way Out’? Stigma May Keep Many From Weight Loss Surgery
December 16, 2018 - Gout drug may protect against chronic kidney disease
December 16, 2018 - Talking about memories enhances the wellbeing of older and younger people
December 16, 2018 - Occupational exposure to pesticides increases risk for cardiovascular disease among Latinos
December 16, 2018 - A biomarker in the brain’s circulation system may be Alzheimer’s earliest warning
December 16, 2018 - Magnesium may play important role in optimizing vitamin D levels, study shows
December 16, 2018 - The effect of probiotics on intestinal flora of premature babies
December 16, 2018 - Parents spend more time talking with kids about mechanics of using mobile devices
December 16, 2018 - Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
December 16, 2018 - Arterial stiffness may predict dementia risk
December 16, 2018 - Study explores link between work stress and increased cancer risk
December 16, 2018 - Sex work criminalization linked to incidences of violence finds study
December 16, 2018 - Johns Hopkins researchers discover swarming behavior in fish-dwelling parasite
December 16, 2018 - Schistosomiasis prevention and treatment could help control HIV
December 16, 2018 - Early postpartum opioids linked with persistent usage
December 16, 2018 - Johns Hopkins researchers identify molecular causes of necrotizing enterocolitis in preemies
December 16, 2018 - Advanced illumination expands capabilities of light-sheet microscopy
December 16, 2018 - Alzheimer’s could possibly be spread via contaminated neurosurgery
December 16, 2018 - Unraveling the complexity of cancer biology can prompt new avenues for drug development
December 16, 2018 - Inflammatory Bowel Disease, Prostate Cancer Linked
December 16, 2018 - Cannabis youth prevention strategy should target mental wellbeing
December 15, 2018 - Recent developments and challenges in hMAT inhibitors
December 15, 2018 - Sewage bacteria found lurking in Hudson River sediments
December 15, 2018 - CDC selects UMass Amherst biostatistician model that helps predict influenza outbreaks
December 15, 2018 - Researchers reveal brain mechanism that drives itch-evoked scratching behavior
December 15, 2018 - New computer model helps predict course of the disease in prostate cancer patients
December 15, 2018 - Obesity to Blame for Almost 1 in 25 Cancers Worldwide
December 15, 2018 - How the brain tells you to scratch that itch
December 15, 2018 - New findings could help develop new immunotherapies against cancer
December 15, 2018 - World’s largest AI-powered medical research network launched by OWKIN
December 15, 2018 - Young people suffering chronic pain battle isolation and stigma as they struggle to forge their identities
December 15, 2018 - Lifespan extension at low temperatures depends on individual’s genes, study shows
December 15, 2018 - New ingestible capsule can be controlled using Bluetooth wireless technology
December 15, 2018 - Researchers uncover microRNAs involved in the control of social behavior
December 15, 2018 - Research offers hope for patients with serious bone marrow cancer
December 15, 2018 - Link between poverty and obesity is only about 30 years old, study shows
December 15, 2018 - Mass spectrometry throws light on old case of intentional heavy metal poisoning
December 15, 2018 - BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
December 15, 2018 - Study finds that in treating obesity, one size does not fit all
December 15, 2018 - Tenacity and flexibility help maintain psychological well-being, mobility in older people
December 15, 2018 - Study reveals role of brain mechanism in memory recall
December 15, 2018 - High levels of oxygen encourage the brain to remain in deep, restorative sleep
December 15, 2018 - Experimental HIV vaccine strategy works in non-human primates, research shows
December 15, 2018 - Genetically modified pigs could limit replication of classical swine fever virus, study shows
December 15, 2018 - FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
December 15, 2018 - Cost and weight-loss potential matter most to bariatric surgery patients
December 15, 2018 - Cancer Research UK and AstraZeneca open new Functional Genomics Centre
December 15, 2018 - New research lays out potential path for treatment of Huntington’s disease
December 15, 2018 - Prestigious R&D 100 Award presented to Leica Microsystems
December 15, 2018 - Study shows septin proteins detect and kill gut pathogen, Shigella
December 15, 2018 - Study sheds new light on disease-spreading mosquitoes
December 15, 2018 - 2017 Saw Slowing in National Health Care Spending
December 15, 2018 - Monitoring movement reflects efficacy of mandibular splint
December 15, 2018 - Study supports BMI as useful tool for assessing obesity and health
December 15, 2018 - Self-guided, internet-based therapy platforms effectively reduce depression
December 15, 2018 - Organically farmed food has bigger climate impact than conventional food production
Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry

image_pdfDownload PDFimage_print

November 27, 2018

Audience: Consumer, Health Professional, Pharmacy

Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India. The impurity found in Mylan’s valsartan API is known as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen. This chemical is typically found in very small amounts in certain foods, drinking water, air pollution, and certain industrial processes.

Amlodipine/Valsartan combination tablets and Amlodipine/Valsartan/Hydrochlorothiazide combination tablets are used for the treatment of high blood pressure. To date, Teva has not received any reports of adverse events signaling a potential link or exposure to valsartan.

Patients taking Amlodipine / Valsartan combination tablets or Amlodipine / Valsartan / Hydrochlorothiazide combination tablets are advised to continue taking their medication and to contact their pharmacist or physician for advice on alternative treatment. The risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any comparable alternative treatment.

Teva Pharmaceuticals USA is notifying its distributors and customers by certified mail and is arranging for return/reimbursement of returned recalled products.  Distributors and retailers that have product that is being recalled should immediately stop distribution and quarantine any quantities remaining in their control and return the recalled product.

Customers and patients with medical-related questions, information about an Adverse Event or other questions about the Teva products being recalled should contact Teva’s Medical Information by phone at: 888-838-2872, option 3, then, option 4. Live calls are received Monday-Friday, 9:00AM-5:00PM Eastern Time with Voicemail available 24 hours/day, 7 days/week or email druginfo@tevapharm.com.

Adverse reactions or other problems experienced with the use of the products may also be reported to Teva directly at 888-838-2872 or to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Patient safety and product quality is critical to Teva. As always, Teva will continue to partner with, and regularly update, all relevant stakeholders, including regulatory authorities, to resolve

this situation. This issue is not limited to valsartan medicines manufactured and distributed by Teva. Some valsartan-containing products manufactured and distributed by other pharmaceutical companies using the same API supplier may also be affected.

Lots Under Voluntary Recall

The products that are part of this voluntary recall and listed below are packed in bottles. These lots were distributed nationwide to Teva’s Direct Accounts (Wholesale/Distributor/Retail/Repackagers/VA Pharmacy, et. al).

Lot # Exp. Date Product Description / Strength Bottle Size NDC
23X017 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count 0093-7690-98
23X018 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 30 Count 0093-7690-56
23X018 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count 0093-7690-98
23X019 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 30 Count 0093-7690-56
23X019 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count 0093-7690-98
23X020 11/2018 Amlodipine and Valsartan Tablets 5 mg/160 mg 30 Count 0093-7690-56
23X022 4/2019 Amlodipine and Valsartan Tablets 5 mg/160 mg 30 Count 0093-7690-56
23X023 4/2019 Amlodipine and Valsartan Tablets 5 mg/160 mg 30 Count 0093-7690-56
23X023 4/2019 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count 0093-7690-98
23X024 4/2019 Amlodipine and Valsartan Tablets 5 mg/160 mg 90 Count 0093-7690-98
24X012 11/2018 Amlodipine and Valsartan Tablets 10 mg/160 mg 30 Count 0093-7691-56
24X012 11/2018 Amlodipine and Valsartan Tablets 10 mg/160 mg 90 Count 0093-7691-98
24X013 11/2018 Amlodipine and Valsartan Tablets 10 mg/160 mg 30 Count 0093-7691-56
25X028 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 90 Count 0093-7692-98
25X029 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
25X029 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 90 Count 0093-7692-98
25X030 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
25X031 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
25X032 11/2018 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
25X035 4/2019 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
25X037 4/2019 Amlodipine and Valsartan Tablets 5 mg/320 mg 30 Count 0093-7692-56
26X036 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 90 Count 0093-7693-98
26X038 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 90 Count 0093-7693-98
26X039 11/2018 Amlodipine and Valsartan Tablets 30 Count 0093-7693-56
Lot # Exp. Date Product Description / Strength Bottle Size NDC
    10 mg/320 mg    
26X039 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 90 Count 0093-7693-98
26X040 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X041 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X042 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X043 11/2018 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X044 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 90 Count 0093-7693-98
26X045 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 90 Count 0093-7693-98
26X046 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X047 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X048 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X049 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X050 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
26X051 4/2019 Amlodipine and Valsartan Tablets 10 mg/320 mg 30 Count 0093-7693-56
Lot # Exp. Date Product Description/ Strength Bottle Size NDC
18X010 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 5 mg/160 mg/12.5 mg 30 count 0093-7807-56
18X010 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 5 mg/160 mg/12.5 mg 90 count 0093-7807-98
18X011 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 5 mg/160 mg/12.5 mg 30 count 0093-7807-56
20X006 11/2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/12.5 mg 30 count 0093-7810-56
20X006 11/2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/12.5 mg 90 count 0093-7810-98
21X006 11/2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg 30 count 0093-7038-56
21X006 11/2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg 90 count 0093-7038-98
21X007 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg 30 count 0093-7038-56
22X045 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg 30 count 0093-7809-56
22X045 2/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg 90 count 0093-7809-98
22X046 02/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg 30 count 0093-7809-56
22X047 02/2019 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg 30 count 0093-7809-56

Source: FDA

About author

Related Articles